Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer’s disease model

BACKGROUND: Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that lacks any disease-modifying drug for the prevention and treatment. Edaravone (EDR), an approved free radical scavenger, has proven to have potential against AD by targeting multiple key pathologies including amyloi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drug Des Devel Ther
Autori principali: Parikh, Ankit, Kathawala, Krishna, Li, Jintao, Chen, Chi, Shan, Zhengnan, Cao, Xia, Wang, Yan-Jiang, Garg, Sanjay, Zhou, Xin-Fu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6042531/
https://ncbi.nlm.nih.gov/pubmed/30022810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S161944
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi